311 results about "Cyclodextrin Derivatives" patented technology

This invention is directed to compositions comprising a water-miscible organic solvent or solvent mixture and one or more cyclodextrin derivatives soluble in the organic water-miscible organic solvent or solvent mixture. In some embodiments, the composition comprises one or more compounds. The invention is further directed to capsules containing the compositions of the present invention and the administration of pharmaceutically active compounds or molecules to subjects. The invention also includes methods of enhancing the solubility of a compound comprising forming a complex or mixture of a compound with a hydroxybutenyl cyclodextrin and a water-miscible solvent.

The present invention relates to development of efficacious pharmaceutical compositions comprising an anti-angiogenic compound in a therapeutically effective amount complexed with or encapsulated in a cyclodextrin derivative.

A sulfoalkyl ether-alkyl ether cyclodextrin (SAE-AE-CD) derivative is provided. The SAE-AE-CD possesses advantages over known SAE-CD and AE-CD derivatives as well as over the parent cyclodextrin by being more water soluble and less membrane disturbing. The SAE-AE-CD includes at least one sulfoalkyl ether group and at least one alkyl ether group even though the degree of substitution for the functional groups can be different. The SAE functional group can be present in molar excess over the AE functional group and vice versa. The total degree of substitution of the cyclodextrin, with respect to both functional groups, can be varied such that a minority or a majority of the hydroxyl moieties of the CD are derivatized. The SAE-AE-CD derivative can be used to solubilize compounds with insufficient water solubility. In some cases, they also stabilize compounds in solution against degradation or to solubilize degradation products formed during degradation. In addition, SAE-AE-CD can also be used for other purposes such as osmotic agents, agents used to mask the taste of problematic drugs. Surprisingly, while AE-CDs are known to be toxic by being membrane disturbing, SAE-AE-CDs are less membrane disturbing and therefore have greater safety.

Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.

The present invention relates to a process of preparing a water-soluble complex of water-insoluble or sparingly-soluble organic medicines and beta-cyclodextrin derivatives: a. dissolving successively or simultaneously the organic medicines and the beta-cyclodextrin derivatives in organic solvent(s) at certain mole ratio or mass ratio in the presence of suitable amount of water; b. removing the organic solvent from the solution of the step a to obtain aqueous solution of the organic medicine and beta-cyclodextrin derivative; and c. removing water from the aqueous solution to obtain the complex of the organic medicine and beta-cyclodextrin derivative. The invention also provides a sterile water-soluble complex of water-insoluble or sparingly-soluble organic medicines and beta-cyclodextrin derivatives. A fully-water-soluble complex can be prepared from any water-insoluble or sparingly-soluble organic medicines or other organic compounds according to the present invention. Thus, appreciably convenient means are provided for industrial uses of such organic medicine preparations and of other organic compounds.

The invention relates to a butyl phthalide tablet and a preparation method thereof. The butyl phthalide tablet is composed of butyl phthalide solid powders and other medical troche auxiliary materials; wherein, the butyl phthalide solid powders are composed of the components with the following weight percentage: 9 percent to 30 percent of butyl phthalide, 0.01 percent to 1.2 percent of emulsifiers and 70 percent to 90 percent of cyclodextrin or cyclodextrin ramification. The troche which is made with the invention has favorable forming, stable product quality and high dissolution rate.

The invention relates to an insoluble medicine feeding system based on soluble cyclodextrin polymer, with high yield and the application in batch production, wherein said medicine compound is formed by insoluble medicine and cyclodextrin derivant, whose mass ratio is 0.1-100:1; and said insoluble medicine is the one whose solubility is less than 1% in room temperature; the soluble cyclodextrin polymer uses cyclodextrin as crosslink agent to be concentrated with cyclodextrin monomer. The inventive product is not shaped powder, whose average molecular weight can reach 10000.

A liquid preparation of meloxican is prepared from the meloxicam or its medical salt and water-soluble cyclodextrin derivative HP-beta-CD used as solubilizer and stabilizer, proportionally mixing, adding cosolvent, pH regulator and water for injection, heating and membrane filtering. It has long storage time at low temp.

The present invention relates to a medicine composition containing mangiferin and its preparation method. It is characterized by that the mangiferin is contained in the cyclodextrin derivative, and the mixing ratio of both them is as follows: mangiferin 1g and cyclodextrin derivative 3g-30g. It can effectively raise solubility and bioavailability of mangiferin.

The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.

The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.

The invention discloses a pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound, wherein cyclodextrin or a cyclodextrin derivative is used to include the pinocembrin. The inclusion compound contains the pinocembrin and the cyclodextrin or cyclodextrin derivative in a molar ratio of 1:1-100. The inclusion compound can improve the water solubility of the pinocembrin and give good play of the therapeutic action of the pinocembrin. The inclusion compound is suitable for the preparation of sold dosage forms and liquid dosage forms required by clinics, including infusion solution, water injection, powder injection, oral solution, syrup, tablets, capsules, granules and dispersible tablets. The inclusion compound can be used for preparing drugs for preventing and\or treating cardiovascular and cerebrovascular diseases, particularly brain stroke, as well as drugs for preventing and\or treating bacterial and\or fungal infections.

An object of the present invention relates to a tablet which comprises an active ingredient and a cyclodextrin or a cyclodextrin derivative and rapidly disintegrates in the oral cavity, etc. The present invention provides a tablet in which 70% by mass or more of the components of the tablet is a cyclodextrin or a cyclodextrin derivative and a method for manufacturing a tablet comprising the steps of: mixing constituent components of the tablet which comprises as constituent components an active ingredient and a cyclodextrin or a cyclodextrin derivative and in which 70% by mass or more of the total constituent components of the tablet is the cyclodextrin or the cyclodextrin derivative; and subsequently tableting the resultant mixture.

The invention discloses a dual-response multiple-medicine delivery system based on cyclodextrin. Firstly, through the action of a donor and a receptor, a macrocyclic molecule cyclodextrin serving as a host and a molecule ferrocene group serving as a guest form a self-inclusion complex; the dissociation and the inclusion of the host to the guest can be realized by utilizing redox regulation and control; the effect that a micromolecular medicine is subjected to adsorption-release through a cavity of the cyclodextrin is realized; secondly, a carbon chain containing an acetal group is introduced to connect a derivative of the cyclodextrin and a silicon dioxide microsphere; in an acid environment, an acetal bond is ruptured; the derivative of the cyclodextrin is quitted; a macromolecule is further released. The medicine delivery system provided by the invention has the characteristics of redox and dual response in the acid environment, moreover, can be used for seriatim or synchronously releasing medicine molecules in different sizes, can be used for controlling administration time, a position and a dosage, and has a favorable application prospect.

The invention belongs to the field of a medicinal preparation and specifically relates to a posaconazole solid dispersion and a preparation method of the solid dispersion and drug use. The invention provides a posaconazole solid dispersion and its drug use. The posaconazole solid dispersion contains posaconazole, a cyclodextrin derivative and a water-soluble or enteric carrier material, wherein mass ratio of posaconazole to the cyclodextrin derivative is 1:1-4 or mass ratio of posaconazole to the cyclodextrin derivative to the water-soluble or enteric carrier material is 1:1-4:0.001-3. The posaconazole solid dispersion can remarkably raise dissolution rate of the difficultly-soluble antifungal agent posaconazole in the small intestine and also can significantly enhance bioavailability of posaconazole. By the use of a dosage form prepared from the solid dispersion, the preparation technology is simple, and quality of the dosage form is stable.

The present invention discloses a method for including andrographolide by using cyclodextrin and its medicinal preparation. The andrographolide is an importent active extract of medicinal plant andrographis. Its inclusion method includes: adding 10-60g of cyclodextrin or its derivative into distilled water and dissolving it; adding 6g of andrographolide extract into 5-10 ml of medicinal methyl alcohol, heating and dissolving it; pouring the cyclodextrin aqueous solution into andrographolide ethyl alcohol solution; ultrasonic vibrating mixed solution in ultrasonic generator for 20-30 min., adopting thin-layer chromatography to identify the cyclodextrin-andrographolide inclusion quality. It does not change chemical property and effective activity of the andrographolide, can be prepared intovarious dosage forms.

Disclosed herein is a composition for preparing a nanoporous material. The composition comprises i) a cyclodextrin derivative, ii) a thermostable matrix precursor, and iii) a solvent for dissolving the components i) and ii). The composition enables the preparation of a low dielectric constant film in which nanopores with a size of 20 Å or less are uniformly distributed.

The invention discloses a cyclodextrin supermolecular composite phase-change energy-storage superfine fiber and a preparation method and application thereof and belongs to the field of functional fiber materials. The cyclodextrin supermolecular composite phase-change energy-storage superfine fiber is prepared by following compositions, by mass, 10-100 parts of cyclodextrin or cyclodextrin derivatives, 20-200 parts of phase change substances and 20-100 parts of cellulose polymer through the electrostatic spinning technology, and can be applied to fields of biomedical materials, separating adsorption materials, energy-saving heat-insulating materials and the like. A supermolecular composite fiber is formed by cyclodextrin and phase-change work components through hydrogen bond and other non-covalent interaction, and the phase change substances are enabled to be less prone to desorption from the cellulose polymer while the obtained energy-storage superfine fiber does not need posttreatment processes like surface crosslinking, so that improvement of heat stability of the materials and simplification of preparation process are facilitated. The main raw materials are natural or seminatural products, so that the cyclodextrin supermolecular composite phase-change energy-storage superfine fiber is good in biocompatibility, nontoxic and harmless, easy to degradation, low in cost and environment-friendly.